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Introduction 1
A leading concept in regenerative medicine is transplantation of tissue-specific cells, often 2 supported by biomaterials, to promote tissue repair 1 . While this strategy has achieved some 3 success, its broad clinical application is hindered by various challenges such as high costs, 4 constraints associated with cell isolation and expansion, and limited in vivo engraftment of 5 transplanted cells 2-4 . Instead, mobilizing endogenous cells to augment the innate regenerative 6 ability of tissues has been explored as an alternative [5] [6] [7] [8] . Given that the function of endogenous 7 cells is regulated by their microenvironment, the potential of biomaterials and/or growth 8 factors to create pro-healing niches for endogenous cells has been explored extensively 6, [9] [10] [11] [12] [13] [14] . 9
Meanwhile, naturally-occurring small molecules are also appealing and equally powerful in 10 regulating various cellular functions including tissue-specific differentiation of stem cells 15-17 . 11 Although significant strides have been made in employing small molecules to direct cellular 12 functions in vitro, harnessing small molecules towards tissue repair in vivo still remains 13 limited. 14
15
In this study, we determine whether sequestration of small molecules could be used to 16 augment endogenous cell function leading to improved tissue repair. Adenosine is a small 17 molecule ubiquitously present in the human body which acts as an extracellular signaling 18 molecule through G-protein coupled adenosine receptors 18, 19 . While the physiological 19 concentration of extracellular adenosine is often insufficient to activate adenosine receptors 20 , 20 an increase in extracellular adenosine is observed following tissue injury, which is integral to 21 the natural repair mechanism 18,21-23 . However, this increase is transient as adenosine is rapidly 22 metabolized 24, 25 . Although delivery of adenosine can be employed to activate adenosine 23 signaling and address tissue dysfunctions, in practice, such an approach has remained elusive. 24 This is mainly due to the ubiquitous nature of adenosine and the potential off-target effects 25 associated with its systemic administration [25] [26] [27] . Instead, approaches that localize adenosine 26 signaling at the targeted tissue site can circumvent these limitations and open up new viable 1 therapeutic strategies. 2 3 To this end, we have developed a biomaterial-based approach to sequester extracellular 4 adenosine by capitalizing on its transient surge following trauma or by delivering exogenous 5 adenosine to sustain the activation of adenosine signaling strictly at the injury site. 6
Specifically, we leveraged the ability of boronate molecules to bind to adenosine via dynamic 7 covalent bonding [28] [29] [30] (Fig. 1a) . By employing a 3-(acrylamido)phenylboronic acid (PBA)-8 functionalized polyethylene glycol (PEG) network, we demonstrated in vivo sequestration of 9 adenosine and its application to accelerate bone repair in a murine model ( Fig. 1b) . We used 10 bone fracture as a model, due to its clinical relevance [31] [32] [33] . Bone fracture is also well-suited for 11 studying adenosine-mediated tissue repair, as extracellular adenosine and its receptors play a 12 key role in maintaining bone homeostasis and function 20,22,34 and have been proven to induce 13 osteogenic differentiation of progenitor cells 17, [35] [36] [37] . 14 15
Results and Discussion 16

Scaffolds functionalized with PBA groups sequester adenosine both in vitro and in vivo 17
To examine the PBA-assisted sequestration and release of adenosine, we have created 18 macroporous PEG scaffolds containing varying amounts of PBA (0, 0.5 M, and 1 M as in the 19 reaction mixture), termed as PBA 0 , PBA 0.5 , and PBA 1.0 , respectively. The macroporous PEG 20 scaffolds were developed by using polymethyl methacrylate (PMMA) microspheres as a 21 porogen, resulting in an interconnected macroporous architecture 38,39 ( Supplementary Fig. 1 ). 22 UV/vis analysis of the residual PBA in the reaction mixture and nuclear magnetic resonance 23 (NMR) spectra of the resulting scaffolds suggest more than 90% of the PBA molecules were 24 reacted and incorporated into the network ( Supplementary Table 1 and Supplementary Fig. 2 ). 25
To determine PBA-mediated adenosine sequestration, the macroporous scaffolds with 26 different levels of PBA were incubated in an excess adenosine solution (6 mg/mL in PBS) for 1 6 h and the bound adenosine was measured using UV/vis spectroscopy. As shown in Fig. 2a , 2 the amount of sequestered adenosine increased as the amount of PBA within the scaffold 3 increased. Specifically, the PBA 1.0 scaffolds had a sequestration efficiency (the amount of 4 PBA moieties involved in adenosine binding) of 75% with a loading capacity (weight 5 percentage of adenosine in the scaffold) of 28%, while those of the PBA 0.5 scaffolds were 6 59% and 11%, respectively ( Fig. 2b) . On the contrary, the PEG scaffolds without PBA 7 moieties (i.e. PBA 0 ) had no detectable adenosine content, suggesting that the loading of 8 adenosine was primarily due to the PBA moieties. Since the PBA 1.0 scaffolds sequestered 9 more adenosine compared to PBA 0.5 , they were used for the rest of the studies. The release of 10 adenosine was tested by incubating the PBA 1.0 scaffolds in a cell culture medium depleted of 11 nucleosides, which showed a robust release during the first 10 d followed by a plateau (Fig.  12 2c,d). 13
14
Having established the ability of PBA scaffolds to sequester and release adenosine in vitro, 15 we next investigated their potential to sequester adenosine in vivo. The ability of PBA 1.0 16 scaffolds to sequester adenosine in vivo was first assessed by using a subcutaneous model. 17
Roughly, 600 μ L of sterile saline solution containing varying amounts of adenosine (0, 0.25 18 or 0.5 mg/mL) was injected into an area adjacent to the scaffolds, which had been implanted 19 subcutaneously into mice for 1 d. The scaffolds were retrieved within 1 h and analyzed for the 20 sequestered adenosine. As anticipated, the PBA 1.0 scaffolds retrieved from the cohort injected 21 with 0.5 mg/mL adenosine had higher adenosine content compared to that received 0.25 22 mg/mL adenosine or saline alone ( Fig. 3a,b) . The PBA 1.0 scaffolds from the cohort that 23 received only the saline injection were also positive for adenosine, albeit a small amount, 24 which is attributed to the endogenous adenosine present at the site of implantation. On the 25 contrary, no adenosine was detected in the PBA 0 scaffolds, further corroborating the necessity 1 of PBA moieties for adenosine sequestration. 2 Although the physiological extracellular adenosine concentration in most organs is low, its 3 level in the extracellular milieu is known to increase following trauma or injury 21, 22 . 4 Consistent with the existing knowledge, our time-dependent analyses of extracellular 5 adenosine following unilateral tibial fracture of mouse showed a significant increase in the 6 adenosine level at the injury site compared to that at the non-fractured contralateral site ( Fig.  7 3c). A roughly 10-fold increase in extracellular adenosine was observed within 1 d following 8 the injury. To determine the ability of PBA scaffolds to sequester extracellular adenosine by 9 leveraging its surge following fracture, scaffolds were implanted at tibial fracture site upon 10 injury and excised after 3 d. Compared to the PBA 0 scaffolds retrieved from the fracture site, 11 those as-retrieved PBA 1.0 scaffolds contained a significantly higher amount of adenosine ( Fig.  12   3d) . This increased adenosine content within the implant was found to be diminished to a 13 concentration similar to pre-fracture levels by 21 d ( Supplementary Fig. 3 ). Together, the 14 results suggest that biomaterials containing PBA molecules can be used to sequester and 15 enrich extracellular adenosine locally in response to injury. 16
17
PBA-Adenosine conjugation promotes stem cell osteogenesis both in vitro and in vivo 18
The osteoanabolic potential of adenosine bound to the scaffold was examined in vitro in a 3D 19 culture by using human mesenchymal stem cells (hMSCs) as a cell source. Towards this, 20 macroporous scaffolds with and without adenosine (PBA 1.0 -ADO and PBA 1.0 , respectively) 21 were loaded with hMSCs and cultured in growth medium (GM). Cell-laden PBA 1.0 scaffolds 22 cultured in osteogenic-inducing medium (OM) were used as a positive control. We have 23 previously shown that macroporous scaffolds with an interconnected macroporous structure 24 can facilitate infiltration of the loaded cells, allowing their homogenous distribution within the 25 scaffold 38,39 . PicoGreen DNA assay as a function of culture time showed comparable levels of 26 DNA content in all groups ( Supplementary Fig. 4 ). Osteogenic differentiation of hMSCs in 1 various culture conditions was evaluated through time-resolved quantitative analyses for 2 multiple osteogenic genes − osteocalcin (OCN), osteopontin (OPN) and osterix (OSX). As 3 shown in Fig. 4a , the expressions of OCN, OPN, and OSX were consistently up-regulated 4 throughout 21 d of culture in the PBA 1.0 -ADO scaffolds similar to the positive control. In 5 contrast, the expressions of osteogenic markers remained low in corresponding cultures with 6 scaffolds lacking adenosine. Consistent with these findings, quantification of calcium content 7 exhibited significantly higher calcium deposition in the PBA 1.0 -ADO scaffolds compared to 8 the PBA 1.0 scaffolds with the same culture condition at the end of 21 d (Fig. 4b) . These results 9 suggest that the sequestered adenosine within the scaffolds promoted osteogenic 10 differentiation of hMSCs akin to cultures involving medium supplemented with 11 adenosine 17,35 . 12
13
We next evaluated the potential of adenosine-bound scaffolds to support in vivo bone 14 formation by adopting an ectopic model 40 . Both PBA 1.0 -ADO and PBA 1.0 scaffolds loaded 15 with hMSCs were implanted into the subcutaneous space of immunodeficient mice for 28 d. 16
Upon retrieval, the PBA 1.0 -ADO scaffolds were found to be opaque ( Fig. 4c and 17 Supplementary Fig. 5 ). Radiographs generated from the microcomputed tomography (μCT) 18 scans showed a strong optical signal from the PBA 1.0 -ADO scaffolds, which is consistent with 19 the gross appearance, suggesting in vivo calcification and the presence of hard tissue 20 formation (Fig. 4c) . The 3D rendering of the excised PBA 1.0 -ADO scaffolds showed an even 21 distribution of mineral deposition within the scaffolds, as indicated by both top and oblique 22 views ( Fig. 4d) . Conversely, the excised PBA 1.0 scaffolds did not display this opaque 23 appearance nor apparent calcification. Based on the quantification of μ CT results, the PBA 1.0 -24 ADO scaffolds had a bone volume ratio (BV/TV) of 14.4% and a bone mineral density 25 (BMD) of 0.51 g/cm 3 , compared to 1.6% and 0.05 g/cm 3 found within the PBA 1.0 group (Fig.  26 4e). Measurement of calcium content within the scaffolds, 97.3 ± 4.8 mg/g dry weight in the 1 PBA 1.0 -ADO and 18.2 ± 0.8 mg/g dry weight in the PBA 1.0 scaffolds ( Fig. 4f) , further 2 confirmed higher in vivo calcification of the cell-laden PBA 1.0 -ADO scaffolds. 3 4 Bone tissue formation was further evaluated by histological characterization. Hematoxylin 5 and eosin (H&E) staining of the excised implants showed dense extracellular matrix (ECM), 6 resembling that of the bone tissue, in the cell-laden PBA 1.0 -ADO scaffolds, whereas the 7 corresponding PBA 1.0 group had minimal bone tissue formation ( Fig. 4g ). Furthermore, 8 positive staining of OCN, an ECM protein secreted by osteoblasts, was seen throughout the 9 PBA 1.0 -ADO scaffolds ( Fig. 4g) . Together, the findings suggest that the adenosine-loaded 10 scaffolds supported osteogenic differentiation of the transplanted hMSCs and promoted 11 ectopic bone formation, which further corroborates the osteoblastogenic function of 12 adenosine. 13
14
PBA-mediated adenosine sequestration promotes bone fracture healing 15
We employed a tibial fracture model to investigate the role of biomaterial-assisted 16 sequestration of adenosine in bone repair, which is a comprehensive process involving 17 cartilaginous callus formation at the injury site, endochondral ossification within the callus, 18 and callus/bone remodeling 41 . Stabilized fractures were induced unilaterally at tibial midshafts 19 in mice 42 , and biomaterials with uniform dimensions were used to cover the fracture sites. In 20 addition to PBA 0 and PBA 1.0 patches, we also used patches pre-loaded with exogenous 21 adenosine (PBA 1.0 -ADO). We monitored the fracture healing as a function of time using 22 radiographic and histomorphometric analyses. groups owing to the minimal mineralization of the calluses. As time progressed, the calluses 2 calcified, and the extent of mineralization was found to correlate with the type of intervention, 3 where both the PBA 1.0 -ADO and the PBA 1.0 groups exhibited a better bridging of the fracture. 4
By 21 d, growing calluses eventually bridged the fracture gaps in all groups. Interestingly, 5 radiographic images at 21 d showed cortical bridging only in groups treated with PBA 1.0 -6 ADO and the PBA 1.0 (Figure 5a,b ), suggesting faster healing compared to those treated with 7 PBA 0 41 . Concomitant with these observations, analysis of the fracture sites at 21 d from the 8 axial view (Figure 5c ) revealed better remodeled patterns and more organized lamellar bone 9 formation in cohorts that received either PBA 1.0 -ADO or PBA 1.0 patches. These findings were 10 further confirmed by the quantification of the μ CT scans at 14 d (Figure 5d ) and 21 d ( Figure  11 5e). By 14 d, bone volume was higher in both the PBA 1.0 -ADO and the PBA 1.0 groups, albeit 12 with no statistical significance. The differences in bone formation were apparent by 21 d, 13
where the fractures treated with PBA 1.0 -ADO and PBA 1.0 exhibited significantly higher bone 14 volume ratio within the calluses compared to those treated with PBA 0 . Together, the results 15 demonstrate the prevalent role of localized adenosine signaling in promoting callus 16 maturation and fracture healing. When the biomaterial patch was dosed once with exogenous 17 adenosine, as in the case of the PBA 1.0 -ADO group, the healing was further improved, mostly 18 due to the higher amount of adenosine available. 19 20 Given the importance of the evolution of cartilaginous tissue, vascularization, and osteoclast-21 driven bone resorption in fracture healing 41 , we also examined the effect of biomaterial-22 mediated adenosine signaling on cartilaginous tissue, blood vessel formation, and osteoclast 23 activity during healing. We observed intense cartilage formation (stained red) within the 24 calluses of both the PBA 1.0 -ADO and the PBA 1.0 groups at 7 d ( Fig. 6a) , followed by cartilage 25 resorption over time suggesting endochondral ossification. In contrast, the animals treated 26 with the PBA 0 showed delayed cartilaginous tissue formation and remodeling. Cartilaginous 1 tissues still remained in the calluses of these animals at 21 d (Fig. 6a) . Concurrent with these 2 findings, an intervention-specific change in vascularization of the calluses was also observed 3 ( Fig. 6b-e ). Specifically, more endomucin (EMCN)-positive blood vessels were detected in 4 both the PBA 1.0 -ADO and the PBA 1.0 groups compared to the PBA 0 cohort at 7 d ( Fig. 6c) and 5 14 d (Fig. 6d) . The improved callus vascularization in the presence of PBA-mediated 6 adenosine signaling may be directly linked to the established role of adenosine in promoting 7 angiogenesis 43, 44 . The improved osteoblastogenesis observed in these groups could also 8 contribute to the increased angiogenesis 45, 46 . While there were differences in angiogenesis 9 among the different groups at early time points, no intervention-dependent differences in 10 blood vessel content were observed at 21 d (Fig. 6e) . Analyses of osteoclast activity via 11 TRAP staining ( Supplementary Fig. 6a ) showed increased TRAP-positive area with time in 12 all the groups. Particularly, higher percentage of TRAP-positive area in the PBA 1.0 -ADO 13 cohort at 21 d ( Supplementary Fig. 6b ), indicating greater bone remodeling, which could be 14 associated with high levels of bone formation. 15
16
To summarize, the cohorts treated with PBA 1.0 or PBA 1.0 -ADO showed a better healing 17 outcome compared to those treated with PBA 0 , as evidenced by the extent of callus maturation, 18 endochondral calcification, and angiogenesis, suggesting that biomaterial-mediated 19 localization of adenosine signaling promotes bone healing. Furthermore, the increased 20 adenosine concentration from the biomaterial-mediated sequestration recedes to the 21 physiological level with healing ( Supplementary Fig. 3 ), which underscores the translational 22 potential of the described strategy. While PBA-mediated sequestration of endogenous 23 adenosine alone promoted fracture healing, the augmentation of adenosine level with a one-24 time supplement of exogenous adenosine (i.e. PBA 1.0 -ADO) further improved callus 25 vascularization and healing outcome. Note that while the PBA 1.0 sequestered only a small 26 fraction of the adenosine being released by cells ( Fig. 3d) , further improvement of biomaterial 1 design, such as increasing PBA content or changing the architecture to increase surface-to-2 volume ratio, could be used to enhance the sequestration efficiency. Such an approach will 3 imbibe more adenosine from the milieu following injury and sustain its local concentration 4 and could eliminate the need for exogenous adenosine entirely. Nonetheless, the results 5 presented in this study showed the potential of using a PBA-containing biomaterial to boost 6 the adenosine concentration at the fracture site and leverage the natural repair mechanism 7 involving adenosine signaling to promote fracture healing. 8 9
Conclusion and Outlook 10
This proof-of-concept study demonstrates that sequestration of adenosine, a native small 11 molecule, by biomaterials at the fracture site can be used to promote bone fracture healing. 12
The sequestration and release of adenosine was achieved by harnessing the ability of boronate 13 molecules to form dynamic covalent bonds with cis-diol molecules such as adenosine. This 14 biomaterial approach sustained an elevated concentration of adenosine locally by leveraging 15 the surge of extracellular adenosine following injury and created a pro-regenerative milieu 16 through localized adenosine signaling, resulting in improved bone repair. Besides 17 sequestering endogenous adenosine, the biomaterial can also be used to deliver exogenous 18 adenosine to the injury site, especially in pathological situations encountering diminished 19 extracellular adenosine. By enabling prolonged adenosine signaling, this biomaterial approach 20 circumvents potential off-target effects associated with the systemic administration of 21 adenosine, which is a major hurdle in harnessing adenosine signaling as a potential 22 therapeutic. 23
24
Moving forward, the biomaterial-assisted sequestration of extracellular adenosine can be used 25 to create an in-situ stockpile of the small molecule, which can be conveniently replenished 26 non-invasively through injections. For example, local modulation of the adenosine signaling 1 may be used to prevent repeated fractures, which are commonly observed in the aged 2 population, as well as in patients suffering with osteoporosis and other bone-degenerating 3 diseases. In the future, age-and sex-dependent fracture healing in response to extracellular 4 adenosine can also be examined to determine how the adenosine metabolism may differ and 5 lead to different repair outcomes. The biomaterial can be adapted accordingly to mirror the 6 innate repair mechanism by modulating the extent of adenosine sequestration. NOD.CB17-Prkdcscid/J mice (4-month-old, Jackson Lab) were used for subcutaneous 23 implantation of hMSC-laden PBA scaffolds with and without adenosine. Female C57BL/6J 24 mice (4-month-old, Jackson Lab) were used for all the experiments involving acellular 25 scaffolds and patches. The mice were anesthetized with 2% isoflurane and administered with 26 buprenorphine (1 mg/kg, sustained release, ZooPharm) through subcutaneous injection prior 1 to surgical procedure. For subcutaneous implantation 40 , a roughly 1 cm-long incision was 2 made on the back of each anesthetized mouse, and each cell-laden scaffold was implanted to 3 the right side of the subcutaneous pouch. For tibial fracture 42 , the right tibia was first 4 stabilized by inserting a 0.7 mm pin from the tibial plateau through the medullary cavity after 5 removal of the skin proximal to the knee, a fracture was then created at the tibial midshaft 6 with blunt scissors, and an 8 mm by 3 mm biomaterial patch was wrapped around the fracture 7 site and held tight underneath the muscle. Upon completion, two drops of bupivacaine (0.5%, 8 Hospira) were applied topically along the incision line, followed by closure with wound clips. Cat# N5000), and 1.1 mg/mL fast red TR (Sigma, Cat# F6760) for 1 h at 37°C. After rinsing 17 in deionized water, the sections were counterstained in Mayer's hematoxylin solution (Sigma, 18 Cat# MHS16) for 1 min. All the stained sections were subsequently dehydrated, covered with 19 a mounting medium (Fisher Scientific, Cat# SP15-100), and imaged using a Keyence (BZ-20 X710) microscopy system. 21
22
Immunofluorescence imaging and vessel quantification: Rehydrated tibia sections were 23 steam-treated in a citrate buffer (pH 6.0; Abcam, Cat# ab64236) for antigen retrieval and 24 further immersed in blocking buffer for 1 h at room temperature. The sections were then 25 incubated with endomucin primary antibody (1:100 in blocking buffer, rat polyclonal; Abcam, 26 1 blocking buffer, Alexa Fluor 647-rabbit anti-rat; Abcam, Cat# ab169349) at room temperature 2 for 1 h. All the sections were subsequently rinsed in PBS and mounted with an antifade 3 medium containing DAPI (Invitrogen, Cat# P36971). Images were acquired using a Zeiss 4 (Axio Imager Z2) microscopy system under the same exposure time for all groups. 5
Quantification of blood vessel formation in calluses was conducted by using ImageJ (v1.52g) 6 and represented as the percentage of EMCN-positive vessel area (red) to the callus area (blue) 7 based on the immunofluorescence images. Ten images from each mouse tibia were used, and 8 five mice from each group were included for the analysis. a, Amount of adenosine sequestered in each subcutaneously implanted scaffold following the 2 injection of saline, 0.25 mg/mL and 0.5 mg/mL adenosine solution, respectively (n=3 3 scaffolds for each injection condition). b , Table lists the injection conditions, the amount of  4 adenosine injected, and the amount of adenosine sequestered in vivo by each scaffold (n=3 5 scaffolds for each injection condition). c, Extracellular adenosine level in bone marrow before 6 and after the unilateral fracture. Bone marrow contents from both the fractured limb and the 7
non-fractured limb were tested (n=3 bone marrow specimens for each condition). d, Scaffolds 8
were excised from the fracture site at 3 d post implantation, and the sequestered adenosine 9 was quantified (n=8 scaffolds for each group). All data are presented as means (± s.d.). One-10
way ANOVA with Tukey's multiple-comparisons test was used for statistical analysis in a; a 11 two-tailed t-test (unpaired) was used for c and d. Significance is determined as *P < 0.05, **P 12 < 0.01, ***P < 0.001, and n.s. (not significant). 13 14 15 16 Expression levels of osteogenic markers (OCN, OPN, and OSX) were quantified as a function 4 of time and presented as fold change against 18s levels (n = 3 purified gene specimens for 5 each group). GM: growth medium; OM: osteogenic-inducing medium. b, Calcium content in 6 each scaffold at 21 d (n = 3 scaffolds for each group). c, Representative photos and 7
corresponding radiographs of the cell-laden PBA 1.0 and PBA 1.0 -ADO scaffolds excised at Day 8 28 post subcutaneous implantation (n = 5 scaffolds for each group). Scale bars, 1 mm. d, 3D 9
reconstruction of a retrieved cell-laden PBA 1.0 -ADO scaffold shows the distribution of 10 calcification, presented in both top view and oblique view. Scale bars, 1 mm. e, Bone volume 11 ratio (BV/TV) and bone mineral density (BMD) of the retrieved scaffolds were quantified 12 based on microcomputed tomography (n = 5 scaffolds for each group). f, Calcium content in 13 each scaffold at Day 28 (n = 5 scaffolds for each group). g, Representative microscopic 14 images of H&E staining and OCN immunohistochemical staining within the retrieved 15 scaffolds (n = 5 scaffolds for each group). 1, neo-bone tissue; 2, scaffold; 3, OCN-positive 16 tissue. Scale bars, 100 μm. All data are presented as means (± s.d.). One-way ANOVA with 17
Tukey's multiple-comparisons test was used for statistical analysis in b; a two-tailed t-test 18 (unpaired) was used for a (with reference to the group of PBA 1.0 [GM] at 7 d), e, and f. 19 Significance is determined as **P < 0.01, ***P < 0.001, ****P < 0.0001, and n.s. (not 20 significant). 21 22 based on microcomputed tomography (n = 6 mice for the cohort treated with PBA 1.0 -ADO, n 10 = 7 mice for the cohort treated with PBA 1.0 or PBA 0 ). e, Bone volume ratio (BV/TV) of 11 calluses at 21 d was quantified (n = 7 mice for the cohort treated with PBA 1.0 -ADO, n = 6 12 mice for the cohort treated with PBA 1.0 or PBA 0 ). In d and e, data are presented as means (± 13 s.d.). One-way ANOVA with Tukey's multiple-comparisons test was used for statistical 14 analysis in d and e. Significance is determined as *P < 0.05, **P < 0.01, ***P < 0.001, and 15 n.s. (not significant). immunofluorescence images (n = 5 mice from each treatment; each data point is averaged 12 from 5 images for each mouse). In c-e, data are presented as means (± s.d.). One-way 13 ANOVA with Tukey's multiple-comparisons test was used for statistical analysis in c-e. 14 Significance is determined as *P < 0.05, **P < 0.01, and n.s. (not significant). 15
